Dublin, Feb. 05, 2019 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
Global Active Pharmaceutical Ingredients market accounted for $151.89 billion in 2017 and is expected to reach $308.48 billion by 2026 growing at a CAGR of 8.2% from 2017 to 2026.
Increase in incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals are some factors fueling the market growth. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries are restricting the market growth.
Active pharmaceutical ingredients are any substance or combination of substances used in a finished pharmaceutical product with pharmacological activity. Active Pharmaceutical Ingredients are chemically and biologically active components of drugs with direct effect in cure, mitigation, treatment and prevention of diseases. An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical substance or drug.
Amongst Customer Base, Generic segment accounted for significant market share during the forecast period. Generic drugs benefit from the patent expiration of innovative drug as it makes them readily available in the market. The demand to produce quality medicines at lower and affordable costs creates a scenario, where the needs for generic drugs increase.
By geography, Asia Pacific dominated the market due to the rising healthcare spending which has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares across the region.
What our report offers:
Key Topics Covered:
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.5 Research Sources
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Active Pharmaceutical Ingredients Market, By Drug Type
5.1 Introduction
5.2 Generic Prescription
5.3 Innovative Drugs
5.4 Over-the-counter (OTC) Drugs
5.5 Prescription Drugs
5.6 Potency
5.6.1 Low to Moderate Potency
5.6.2 Potent to Highly Potent
6 Global Active Pharmaceutical Ingredients Market, By API Formulation
6.1 Introduction
6.2 Innovative API
6.3 Generic API
7 Global Active Pharmaceutical Ingredients Market, By Type of Manufacturer
7.1 Introduction
7.2 Contract Manufacturers
7.3 Captive Manufacturers
7.4 Merchant API Manufacturers
7.4.1 Generic Merchant API Manufacturers
7.4.2 Innovative Merchant API Manufacturers
8 Global Active Pharmaceutical Ingredients Market, By Type of Synthesis
8.1 Introduction
8.2 Biotech Active Pharmaceutical Ingredients
8.2.1 Type
8.2.1.1 Biosimilars
8.2.1.2 Innovative Biotech APIs
8.2.2 Expression System
8.2.2.1 Insect Expression Systems
8.2.2.2 Mammalian Expression Systems
8.2.2.3 Microbial Expression Systems
8.2.2.4 Plant Expression Systems
8.2.2.5 Yeast Expression Systems
8.2.3 Product
8.2.3.1 Blood Factors
8.2.3.2 Cytokines
8.2.3.3 Fusion Proteins
8.2.3.4 Hormones and Growth Factors
8.2.3.5 Monoclonal Antibodies
8.2.3.6 Therapeutic Enzymes
8.2.3.7 Vaccines
8.3 Synthetic Active Pharmaceutical Ingredients
8.3.1 Generic Synthetic APIs
8.3.2 Innovative Synthetic APIs
9 Global Active Pharmaceutical Ingredients Market, By API Type
9.1 Introduction
9.2 Biological API
9.3 Chemical API
10 Global Active Pharmaceutical Ingredients Market, By Molecule
10.1 Introduction
10.2 Large Molecule
10.3 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, By Application
11.1 Introduction
11.2 Anti-diabetic Drugs
11.3 Cardiovascular Disease
11.4 Central Nervous System and Neurological Disorders
11.5 Diabetes
11.6 Endocrinology
11.7 Gastrointestinal Disorders
11.8 Musculoskeletal drugs
11.9 Non-steroidal Anti-inflammatory Drugs
11.10 Oncology
11.11 Orthopedic Disorders
11.12 Respiratory
11.13 Urology
11.14 Other Applications
12 Global Active Pharmaceutical Ingredients Market, By Geography
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 Company Profiling
14.1 Teva Active Pharmaceutical Industries Limited
14.2 Ranbaxy Laboratories
14.3 Pfizer, Inc
14.4 Novartis
14.5 Mylan N.V
14.6 Lupin
14.7 Dr. Reddy's Lab
14.8 Boehringer Ingelheim GmbH
14.9 Aurobindo pharma
14.10 Albemarle Corporation
14.11 Ceva Animal Health, Inc.
14.12 Virbac
14.13 Sun Pharmaceutical Industries Ltd.
14.14 Merck Animal Health (U.S.)
14.15 Elanco Animal Health (U.S.)
14.16 Zoetis (U.S.)
14.17 Merial Inc. (Sanofi) (France)
14.18 Bioniche Animal Health (Canada)
14.19 Bayer Healthcare (Germany)
14.20 ELI Lilly and Company
14.21 Glaxosmithkline PLC
14.22 Abbvie Inc.
14.23 Sanofi
14.24 Bristol-Myers Squibb
For more information about this report visit https://www.researchandmarkets.com/research/q43b94/300_billion?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Pharmaceutical Intermediates